Oncopeptides launches glioblastoma study in Oslo after regulatory clearance

Oncopeptides said it is moving into glioblastoma research, citing swift regulatory clearance to start a Window-of-Opportunity clinical study in Oslo. Preclinical and translational glioblastoma findings were accepted for poster presentation at the EANO 2026 congress in Rome on Sept. 24-27.